A phase I study to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activities of daily oral BAL101553, a novel tumor checkpoint controller (TCC) in adult patients with progressive or recurrent glioblastoma (GBM) or high-grade glioma.
Year: 2017
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Alvaro Henrique Ingles Garces, Elizabeth R. Plummer, Juanita Suzanne Lopez, Rebecca Sophie Kristeleit, Julie MacDonald, Lorna Sweeting, Michael-John Devlin, Yvette Drew, Alison L. Hannah, Nicola Aceto, Stephanie Anderson, Heidi A Lane, Patrice Larger, Martina Maurer, Phil McKernan, Marc Frederick Engelhardt, Alastair Greystoke, Niamh Coleman, T.R. Jeffry Evans, Paul James Mulholland
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2780145751